SeedFolio
SeedFolio is a San Diego–based venture capital firm that invests early in teams developing novel technologies to 'conquer disease' or 'clean the planet.' The firm uses a structured sourcing and selection process and targets companies with high reward/risk ratios.
SeedFolio
Services
Early-stage equity investments
Provides seed-stage equity investments (primary check size $300k); prefers priced rounds and will occasionally invest via convertible notes or SAFEs.
Lead investor services for small raises
Can lead priced rounds for US companies where the total raise does not exceed $2M; negotiates a board seat vote among preferred investors and prepares deal documentation and legal due diligence via partnered law firms (capped fee).
Deal analysis and documentation
Performs a multi-step diligence and analysis process (screen, analyze, quantify, verify, invest) including probability-weighted return calculations and produces a detailed (10+ page) deal memo on deals they lead.
Post-investment support and network access
Provides ongoing support after investment and partners with incubators, tech-transfer offices, and other VCs to connect portfolio companies with resources and partners.
Founder & partner intake channel
Accepts non-confidential pitch decks or recorded pitch videos via a partner intro email address for initial evaluation.
Early-stage equity investments
Provides seed-stage equity investments (primary check size $300k); prefers priced rounds and will occasionally invest via convertible notes or SAFEs.
Lead investor services for small raises
Can lead priced rounds for US companies where the total raise does not exceed $2M; negotiates a board seat vote among preferred investors and prepares deal documentation and legal due diligence via partnered law firms (capped fee).
Deal analysis and documentation
Performs a multi-step diligence and analysis process (screen, analyze, quantify, verify, invest) including probability-weighted return calculations and produces a detailed (10+ page) deal memo on deals they lead.
Post-investment support and network access
Provides ongoing support after investment and partners with incubators, tech-transfer offices, and other VCs to connect portfolio companies with resources and partners.
Founder & partner intake channel
Accepts non-confidential pitch decks or recorded pitch videos via a partner intro email address for initial evaluation.
Portfolio
Listed as 'ACQUIRED. Improving lower pelvic surgeries with faster safer ureter identification.'
#MedTech / Surgical devices
Described as faster and 10x cheaper than PCR; point-of-care molecular diagnostics platform.
#Diagnostics / Point-of-care molecular diagnostics
Developing one-time Dok7-gene therapy for diseases of the neuromuscular junction (including congenital myasthenia syndrome, ALS, muscular dystrophies).
#Gene therapy / Biotech
Uses ultrasensitive dPCR expanded from 6 to 63 channels for specific-pathogen identification; aims for sepsis pathogen ID at point-of-care in ~2 hours.
#Diagnostics / dPCR
Develops a mechanoporation device for non-viral ex-vivo transfection with higher efficiency and viability than electroporation.
#Biotechnology / Cell processing
Developer of a better/safer version of irofulven and a precision-medicine approach to treat multiple cancer types.
#Biopharma / Oncology
Listed as 'ACQUIRED. Improving lower pelvic surgeries with faster safer ureter identification.'
#MedTech / Surgical devices
Described as faster and 10x cheaper than PCR; point-of-care molecular diagnostics platform.
#Diagnostics / Point-of-care molecular diagnostics
Developing one-time Dok7-gene therapy for diseases of the neuromuscular junction (including congenital myasthenia syndrome, ALS, muscular dystrophies).
#Gene therapy / Biotech
Uses ultrasensitive dPCR expanded from 6 to 63 channels for specific-pathogen identification; aims for sepsis pathogen ID at point-of-care in ~2 hours.
#Diagnostics / dPCR
Develops a mechanoporation device for non-viral ex-vivo transfection with higher efficiency and viability than electroporation.
#Biotechnology / Cell processing
Developer of a better/safer version of irofulven and a precision-medicine approach to treat multiple cancer types.
#Biopharma / Oncology